Shanhe Pharmaceutical Auxiliary Co., Ltd.

Legal Opinion Letter from Anhui Tianhe Law Firm Regarding the 2025 Annual Shareholders' Meeting of Anhui Shanhe Pharmaceutical Excipients Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Guoyuan Securities Co., Ltd. 2025 Annual Continuous Supervision Regular On-site Inspection Report of Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd.

Guoyuan Securities Co., Ltd. Verification Opinion on the Storage, Management, and Use of Fundraising by Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd. in 2025

Guoyuan Securities Co., Ltd. 2025 Annual Continuous Supervision Tracking Report of Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd.

Guoyuan Securities Co., Ltd. Verification Opinion on the Adjustment of Internal Investment Structure of Some Fundraising Projects of Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd.

Guoyuan Securities Co., Ltd. Summary Report on the Sponsorship of Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd. for the Issuance of Convertible Corporate Bonds to Unspecified Objects

Announcement on the Confirmation of the 2025 Annual Compensation for Directors and Senior Management and the 2026 Annual Compensation Plan

2025 Independent Director's Work Report Wang Hong

2025 Independent Director's Work Report Zhou Jianping

2025 Independent Director's Work Report Lin Ping

Announcement on Holding the 2025 Performance Presentation and Question Collection

Verification Opinion of Guoyuan Securities Co., Ltd. on the Self-evaluation Report of Internal Control for 2025 of Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd.

Internal Control Audit Report

Internal Control Evaluation Report for 2025

Compensation Management System for Directors and Senior Management (April 2026)

Announcement on the Company's Product Obtaining the DMF Filing Number from the US FDA

Announcement on Adjusting the Internal Investment Structure of Some Fundraising Investment Projects

Progress Announcement on the Company's Use of Part of the Idle Self-owned Funds for Entrusted Wealth Management

Announcement on the Company's Guarantee for Its Wholly-owned Subsidiary

Announcement on the Company's Financial Assistance to Its Wholly-owned Subsidiary

Notice of the 2025 Shareholders' Meeting

Announcement of the Resolution of the Tenth Meeting of the Sixth Board of Directors

Announcement on the Profit Distribution Plan for 2025

Q1 2026 Report

Special Report on the Storage, Management, and Use of Raised Funds for 2025

Verification Report on the Annual Storage, Management, and Use of Raised Funds

Evaluation Report on the Performance of the Accounting Firm

Report of the Board of Directors' Audit Committee on the Evaluation of the Accounting Firm's Performance and Supervisory Responsibilities for 2025

Special Explanation on Non-operating Fund Occupation and Other Related Fund Transactions

Summary Table of Non-operating Fund Occupation and Other Related Fund Transactions for 2025

Special Opinion of the Board of Directors on the Independence Assessment of Independent Directors

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Verification opinion from Guoyuan Securities Co., Ltd. regarding the use of part of the idle raised funds for cash management and part of the idle self-owned funds for entrusted wealth management by Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd.

Announcement on the use of part of the idle raised funds for cash management and part of the idle self-owned funds for entrusted wealth management

Announcement on the conversion of convertible bonds in the first quarter of 2026

Announcement on the Completion of the Implementation of the Share Reduction Plan by Shareholders Holding Over 5%